Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02142959 · ClinicalTrials.gov registry record · Phase 2
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Phase 2 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
NCT02142959 is a Phase 2 study that has completed, run by Biogen. The registered enrollment target is 187 participants.
The verdict
NCT02142959, a Phase 2 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
Study Summary
Radiation dermatitis is experienced by almost all patients (up to 95%) receiving radiation therapy for cancer. Radiation dermatitis can be a serious condition because, in addition to its direct physical complications and the resulting impact on overall quality of life, it can also be a dose-limiting toxicity requiring changes to the prescribed course of radiation therapy. The most common strategy employed in an attempt to prevent or minimize radiation dermatitis involves moisturization of the irradiated area, use of a mild soap to keep the area clean, and minimizing exposure to potential mechanical irritants, such as scratching and rough clothing. However, this strategy has been shown to lack clinically significant efficacy. Consequently, there is a clinical need for new treatments that are effective in protecting against radiotherapy-induced oxidative stress and the subsequent development of radiation dermatitis. Based on data from previous studies in animals and humans, Reata believes that omaveloxolone (RTA 408) Lotion may effectively prevent and mitigate radiation dermatitis in oncology patients undergoing radiation therapy. This randomized, double-blind, vehicle-controlled, parallel-group trial will study the efficacy, tolerability and safety of two concentrations of omaveloxolone (RTA 408) Lotion (3% and 0.5%) versus vehicle in patients with breast cancer for whom radiation therapy is recommended.
Interventions
- DRUG Vehicle Lotion
- DRUG Omaveloxolone Lotion 0.5%
- DRUG Omaveloxolone Lotion 3%
- RADIATION 3D conformal radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2014-06-30 |
| Est. Completion | 2015-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02142959
The ClinicalTrials.gov registry entry for NCT02142959 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vehicle Lotion is the first listed.
NCT02142959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02142959 about?
NCT02142959 is a clinical study titled "RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE". Radiation dermatitis is experienced by almost all patients (up to 95%) receiving radiation therapy for cancer. Radiation dermatitis can be a serious condition because, in addition to its direct physical complications and the resulting impact on overall quality of life, it can also be a dose-limiting...
What is the current status of trial NCT02142959?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2014-06-30. Estimated completion is 2015-04-30.
What interventions are being tested in trial NCT02142959?
The interventions under investigation include: Vehicle Lotion (DRUG), Omaveloxolone Lotion 0.5% (DRUG), Omaveloxolone Lotion 3% (DRUG), 3D conformal radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT02142959?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.